Navigation Links
Prasco to Market Authorized Generic of ZEGERID®
Date:7/1/2010

CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in the U.S. under the Prasco label.

"We are especially proud to establish this relationship with Santarus and to bring the authorized generic of ZEGERID® to consumers," said Prasco Chief Executive Officer E. Thomas Arington. "With an authorized generic that is manufactured identically to the brand, patients have the benefit of the brand-identical experience at generic savings," stated Arington.

Omeprazole/Sodium Bicarbonate is AB-rated, therapeutically equivalent and substitutable for the brand ZEGERID®. ZEGERID® (omeprazole/sodium bicarbonate) is an immediate-release oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD). These highlights do not include all the information needed to use ZEGERID® safely and effectively. See full prescribing information for ZEGERID® at www.zegerid.com.

ZEGERID® is a registered trademark of Santarus, Inc.

About Prasco

Prasco is a privately-held company located in Cincinnati, Ohio that specializes in selling authorized generics and has partnered with major global pharmaceutical companies to provide patients, pharmacists and customers with generic options that deliver the identical brand experience. The company sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and mail order pharmacies.  For more information, visit www.prasco.com.


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
2. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
3. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
4. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
7. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
8. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):